Clinical Trials Logo

Clinical Trial Summary

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.


Clinical Trial Description

The overall goal of this proposal is to evaluate the efficacy of testosterone replacement therapy in improving fatigue and other outcomes such as sexual function, quality of life, body composition, muscle strength and physical activity in a double-blind, randomized, placebo-controlled trial in young cancer survivors who report fatigue and have testosterone deficiency. Fatigue is one of the most prevalent and debilitating symptoms in men with cancer affecting 70-100% of patients irrespective of their age. Cancer-related fatigue is experienced by patients not only during active cancer treatment, but is also highly prevalent in cancer survivors who exhibit persistent fatigue months to years after the end of their treatment with the highest prevalence being in recipients of chemotherapy and/or radiation therapy. In addition to fatigue, sexual dysfunction is also highly prevalent in male cancer survivors. Male cancer survivors also have increased fat mass and decreased lean body mass, a phenotype that predisposes them to reduced muscle strength. This phenotype of fatigue, sexual dysfunction and adverse body composition is commonly encountered in non-cancer patient populations with testosterone deficiency, a condition which is also highly prevalent (50-90%) in cancer survivors. Pivotal trials of testosterone replacement therapy in non-cancer patient populations have shown an improvement in fatigue, sexual function and body composition in men randomized to testosterone compared with placebo. However, the efficacy of testosterone replacement therapy on cancer-related fatigue has not been studied. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04049331
Study type Interventional
Source Seattle Institute for Biomedical and Clinical Research
Contact Jose M Garcia, MD, PhD
Phone 206 764 2984
Email jg77@uw.edu
Status Recruiting
Phase Phase 2
Start date March 22, 2021
Completion date January 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT04467697 - Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men Phase 3
Completed NCT04326673 - Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
Completed NCT03203681 - Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Phase 4
Completed NCT01904734 - Clomid in Men With Low Testosterone With and Without Prior Treatment Phase 2
Completed NCT00398580 - 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Phase 2
Completed NCT00400335 - Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Phase 1
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT03282682 - Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male N/A
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Terminated NCT05205837 - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Phase 4
Completed NCT03747003 - Gonadal Function in Young to Middle Aged HIV-infected Men
Withdrawn NCT03176537 - Periodontal Profile of Hypogonadic Men Phase 4
Completed NCT03541395 - Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males N/A
Recruiting NCT05249634 - Testosterone Treatment in Men With Chronic Kidney Disease Phase 2
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Withdrawn NCT04717362 - The Effects of Natesto For Treatment Of Hypogonadism Early Phase 1
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Completed NCT04456296 - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Phase 4
Not yet recruiting NCT06312761 - Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 Phase 1/Phase 2
Recruiting NCT05381831 - Natesto Spermatogenesis Reboot Phase 4